Login to Your Account

Skuldtech Readies Companion Diagnostic for TKI Masitinib

By Cormac Sheridan
Staff Writer

Wednesday, November 7, 2012
French diagnostics firm Skuldtech SAS has emerged as the company behind a phenotypic biomarker that offers a simple predictive indication of which pancreatic cancer patients will benefit from an investigational tyrosine kinase inhibitor (TKI) currently under regulatory review in Europe.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription